Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.76B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 3.12M
Average 1.81M
Returns on capital
Ultragenyx Pharmaceutical Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
718.8%
avg -22.1%
ROIC
-43.5%
avg -44.3%
ROA
-37.5%
avg -36.2%
Analysis
ROE is currently the strongest return metric at 718.8% versus its period average of -22.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Emil D. Kakkis | Founder, President, Chief Executive Officer & Director | USD 1.19M | 66 | 132.69K | 0.13% |
Erik Harris | Executive Vice President & Chief Commercial Officer | USD 925.26K | 56 | 49.96K | 0.05% |
John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | USD 923.93K | 60 | 79.94K | 0.08% |
Eric Crombez | Chief Medical Officer & Executive Vice President | USD 882.36K | 53 | 111.19K | 0.11% |
Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer | USD 846.01K | 47 | 89.23K | 0.09% |
Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs | USD 819.87K | 48 | 92.56K | 0.09% |
Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations | USD 331.33K | 61 | 79.94K | 0.08% |
Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President | — | 61 | — | — |
Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer | — | 55 | — | — |
Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | — | 61 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
28
$3.81M
Net Transaction Value
−$3.81M
Net selling
Most Active
Horn Howard
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 15, 26Oct 15, 2026 | Horn Howard Direct | Sell | $107.9K$107,897.82 |
| Sep 15, 26Sep 15, 2026 | Huizenga Theodore Alan Direct | Sell | $17.4K$17,410.31 |
| Sep 3, 26Sep 3, 2026 | Huizenga Theodore Alan Direct | Sell | $2.3K$2,252.39 |
| Aug 3, 26Aug 3, 2026 | Horn Howard Direct | Sell | $117K$117,024.32 |
| Aug 3, 26Aug 3, 2026 | Parschauer Karah Herdman Direct | Sell | $47.3K$47,348.00 |
| Jul 1, 26Jul 1, 2026 | Horn Howard Direct | Sell | $155.6K$155,644.74 |
| Jun 15, 26Jun 15, 2026 | Sanders Corazon (Corsee) D. Direct | Sell | $50.1K$50,100.00 |
| Jun 15, 26Jun 15, 2026 | Parschauer Karah Herdman Direct | Sell | $46.8K$46,753.38 |
| Jun 1, 26Jun 1, 2026 | Horn Howard Direct | Sell | $110.6K$110,601.81 |
| May 18, 26May 18, 2026 | SULIMAN SHEHNAAZ Direct | Sell | $144.2K$144,188.80 |
1–10 of 28
Summary
Insiders reported 0 buys worth $0.00 and 28 sells worth $3.81M over the last 12 months. That adds up to net selling of $3.81M. Horn Howard was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A11 analysts |
| Revenue | N/A | N/A | +22.8% | +15.2% (5yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.8% over three years. Forward estimates point to Revenue at +15.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Ultragenyx Pharmaceutical Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about RARE's management, answered from reported figures.
Who manages RARE?
Ultragenyx Pharmaceutical Inc. (RARE) lists 10 active executives. The top listed executive is Ernie W. Meyer, Chief Human Resources Officer & Executive Vice President.
Are RARE insiders buying or selling?
Recent insider activity shows net buying of $27.09M.
Continue the stock analysis
Jump to another research area for this company.